(October 13, 2005) -- Boston Scientific Corporation (NYSE: BSX) today introduced a new program that will offer participating medical centers in the United States a TAXUS® Express²™ stent system at no additional charge if a patient requires a re-intervention due to in-stent restenosis of a previously implanted TAXUS Express2 stent system. The program will run from January 1, 2006 to December 31, 2006.

“As the worldwide drug-eluting stent market leader, the TAXUS stent system continues to be the drug-eluting stent-of-choice for physicians and their patients,